诱导多功能干细胞在青光眼治疗中的应用研究进展  

Recent advances of induced pluripotent stem cells in glaucoma treatment

作　　者：王霞[1,2] 刘瀛[2] 刘旭[2] 何媛[2] WANG Xia;LIU Ying;LIU Xu;HE Yuan(the Xi’an Medical College Xi’an 710068,Shaanxi Province,China;Department of Ophthalmology,the Second Affiliated Hospital of Xi’an Medical College Xi’an 710038,Shaanxi Province,China)

机构地区：[1]西安医学院,陕西省西安市710068 [2]西安医学院第二附属医院眼科,陕西省西安市710038

出　　处：《眼科新进展》2017年第12期1185-1188,共4页Recent Advances in Ophthalmology

基　　金：国家自然科学基金资助(编号:81100665)~~

摘　　要：青光眼是一组以视神经萎缩和视野缺损为共同特征的疾病,青光眼和其他视神经疾病导致的视网膜神经节细胞(retinal ganglion cells,RGCs)损伤和死亡是引起不可逆的视觉丢失或致盲的一个主要原因。诱导多功能干细胞衍生来的RGCs能够为青光眼提供一种新的细胞治疗法。并且,这些细胞能够在人类RGCs的研究进展、基因调控、神经生物学研究中开拓一个新的视野。本文就诱导多功能干细胞衍生的不同类型细胞在青光眼细胞替代治疗等方面的最新研究和应用进展作一综述,以探讨其临床应用前景。Glaucoma is a disease characterized by optic atrophy and visual field defects.Injury and death of retinal ganglion cells(RGCs)caused by glaucoma and other optic neuropathy are one of the main causes of irreversible visual loss or blindness.RGCs,which are derived from induced pluripotent stem cells,can provide a new cell alternative therapy for glaucoma and a promising prospect for a new field in the research progress,gene regulation and neurobiology of human RGCs.Therefore,this article will give an insight into the latest researches and application progress of different types of cells derived from induced pluripotent stem cells in glaucoma and discuss the clinical application prospects.

关 键 词：青光眼 视网膜神经节细胞 干细胞 诱导多功能干细胞 

分 类 号：R775[医药卫生—眼科]